barinthuslogo.jpg
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
April 18, 2024 16:10 ET | Barinthus Biotherapeutics
Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced topline final data from the APOLLO trial (also known as HPV001).
Digital Utilities Ventures Completes Strategic Merger - Paving the Way for Future Growth and Innovation
April 18, 2024 09:00 ET | Digital Utilities Ventures, Inc.
Digital Utilities Ventures Completes Strategic Merger - Paving the Way for Future Growth and Innovation
IMG_5056
Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects. 
April 17, 2024 10:15 ET | Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most...
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
April 17, 2024 08:00 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
NEW ATAI-Logo_Primary.png
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
April 17, 2024 07:00 ET | atai Life Sciences
BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally.BPL-003 was shown to be safe and well-tolerated with a predictable...
Sound Bioventures.png
Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics
April 17, 2024 03:00 ET | Sound Bioventures
Sound Bioventures joins strong international syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford  New funding enables Theolytics...
nacuity-pharmaceuticals-inc.jpg
Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.
April 16, 2024 09:00 ET | Nacuity Pharmaceuticals, Inc.
FORT WORTH, Texas, April 16, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel treatments for retinitis pigmentosa, cataract, and...
Turnstone Logo.jpg
Turnstone Biologics Appoints William Waddill to its Board of Directors
April 16, 2024 09:00 ET | Turnstone Biologics Corp.
Turnstone Biologics appoints biotechnology industry veteran, William Waddill, to its Board of Directors.
Compass-logo-RGB-outlines.png
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
April 16, 2024 08:00 ET | Compass Therapeutics
The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with advanced solid tumors who progressed on at least one prior regimen containing a...
logo-brainhq-hi-res-hori.png
Study: This Brain Training is Effective for Just About Everyone
April 16, 2024 08:00 ET | Posit Science
SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- A large, long-term study of different types of brain training found only the training in the brain health app BrainHQ, made by Posit Science, was...